Blink Reminders and Meibomian Gland Loss in Digital Screen Users
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorAsociación para Evitar la Ceguera en México
About this trial
This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).
Eligibility criteria
Qualifiers
Participants aged 18 to 40 years.
Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week.
Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms).
Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography.
Disqualifiers
Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis.
History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury.
Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months.
Active use of contact lenses that cannot be suspended for the duration of the 12-week study period.
Trial design
Treatments tested in this trial
- Digital Blink Reminder Software (BlinkEasy)
- Visual Hygiene Education (20-20-20 Rule).
Treatment groups
28 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov